Ceftiofur
- QJ01DD90 (WHO) QJ51DD90 (WHO)
- EU: Rx-only[1]
- (6R,7R)-7-[ [(2Z)-2-(2-Amino-1,3-thiazol-4-yl)- 2-methoxyiminoacetyl]amino]-3-(furan-2- carbonylsulfanylmethyl)-8-oxo-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- 80370-57-6
Y
- 6328657
- 4886668
Y
- 83JL932I1C
- D07657
Y
- ChEMBL222913
Y
- DTXSID7046702
- Interactive image
- O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)/c3nc(sc3)N)CSC(=O)c4occc4)C(=O)O
- InChI=1S/C19H17N5O7S3/c1-30-23-11(9-7-34-19(20)21-9)14(25)22-12-15(26)24-13(17(27)28)8(5-32-16(12)24)6-33-18(29)10-3-2-4-31-10/h2-4,7,12,16H,5-6H2,1H3,(H2,20,21)(H,22,25)(H,27,28)/b23-11-/t12-,16-/m1/s1
Y
- Key:ZBHXIWJRIFEVQY-IHMPYVIRSA-N
Y
Ceftiofur is an antibiotic of the cephalosporin type (third generation), licensed for use in veterinary medicine. It was first described in 1987.[2] It is marketed by pharmaceutical company Zoetis as Excenel,[3] Naxcel, and Excede and is also the active ingredient in that company's Spectramast LC (lactating cow formulation) and Spectramast DC (dry cow formulation) product.[citation needed]
It is resistant to the antibiotic resistance enzyme beta-lactamase, and has activity against both Gram-positive and Gram-negative bacteria. E. coli strains resistant to ceftiofur have been reported.[4]
The metabolite desfuroylceftiofur also has antibiotic activity.[5] The two compounds are measured together to measure for antibiotic activity in milk (alongside other antibiotics).[6]
References
- ^ "Naxcel EPAR". European Medicines Agency. 20 October 2009. Retrieved 29 June 2024.
- ^ Yancey RJ, Kinney ML, Roberts BJ, Goodenough KR, Hamel JC, Ford CW (1987). "Ceftiofur sodium, a broad-spectrum cephalosporin: evaluation in vitro and in vivo in mice". Am. J. Vet. Res. 48 (7): 1050–3. PMID 3631686.
- ^ "Pfizer Animal Health Dairy Information on Products and Solutions". Archived from the original on 13 October 2007. Retrieved 20 November 2007.
- ^ Donaldson SC, Straley BA, Hegde NV, Sawant AA, DebRoy C, Jayarao BM (2006). "Molecular epidemiology of ceftiofur-resistant Escherichia coli isolates from dairy calves". Appl. Environ. Microbiol. 72 (6): 3940–8. Bibcode:2006ApEnM..72.3940D. doi:10.1128/AEM.02770-05. PMC 1489609. PMID 16751500.
- ^ Salmon SA, Watts JL, Yancey RJ (July 1996). "In vitro activity of ceftiofur and its primary metabolite, desfuroylceftiofur, against organisms of veterinary importance". Journal of Veterinary Diagnostic Investigation. 8 (3): 332–336. doi:10.1177/104063879600800309. PMID 8844576.
- ^ "BetaStar Plus / For beta-lactam antibiotics / Product information sheet" (PDF). Neogen. Retrieved 9 September 2014.
- v
- t
- e
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Lipopeptides |
|
---|---|
Other |
|
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e